Published in Carcinogenesis on August 01, 2002
Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr Pharm Des (2013) 1.22
Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice. World J Gastroenterol (2005) 1.18
Dose-dependency of resveratrol in providing health benefits. Dose Response (2010) 1.11
Quercetin induces apoptosis of Trypanosoma brucei gambiense and decreases the proinflammatory response of human macrophages. Antimicrob Agents Chemother (2004) 1.09
Resveratrol accelerates erythroid maturation by activation of FoxO3 and ameliorates anemia in beta-thalassemic mice. Haematologica (2013) 0.99
Resveratrol induces apoptosis in human esophageal carcinoma cells. World J Gastroenterol (2003) 0.96
Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor alpha gene expression via p38MAPK/CK2 signaling in human breast cancer cells. FASEB J (2011) 0.96
Resveratrol reduces radiation-induced chromosome aberration frequencies in mouse bone marrow cells. Radiat Res (2008) 0.95
Resveratrol: Biological and pharmaceutical properties as anticancer molecule. Biofactors (2010) 0.93
Resveratrol-induced cytotoxicity in human Burkitt's lymphoma cells is coupled to the unfolded protein response. BMC Cancer (2010) 0.87
Resveratrol (trans-3,5,4'-trihydroxystilbene) suppresses EL4 tumor growth by induction of apoptosis involving reciprocal regulation of SIRT1 and NF-κB. Mol Nutr Food Res (2011) 0.86
Resveratrol inhibits benzo[a]pyrene-DNA adduct formation in human bronchial epithelial cells. Br J Cancer (2004) 0.83
Resveratrol ameliorates TNFα-mediated suppression of erythropoiesis in human CD34(+) cells via modulation of NF-κB signalling. Br J Haematol (2011) 0.83
Resveratrol, but not dihydroresveratrol, induces premature senescence in primary human fibroblasts. Age (Dordr) (2011) 0.82
Exacerbation of tobacco smoke mediated apoptosis by resveratrol: an unexpected consequence of its antioxidant action. Int J Biochem Cell Biol (2010) 0.80
Resveratrol increases the bone marrow hematopoietic stem and progenitor cell capacity. Am J Hematol (2014) 0.79
Ellagic Acid and Resveratrol Prevent the Development of Cisplatin Resistance in the Epithelial Ovarian Cancer Cell Line A2780. J Cancer (2016) 0.77
Factors influencing the production of stilbenes by the knotweed, Reynoutria x bohemica. BMC Plant Biol (2010) 0.77
Upregulation of FcγRIIB by resveratrol via NF-κB activation reduces B-cell numbers and ameliorates lupus. Exp Mol Med (2017) 0.75
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 17.23
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol (2010) 8.80
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 5.80
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood (2006) 4.61
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood (2006) 3.84
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol (2013) 3.56
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst (2011) 3.51
Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol (2009) 3.21
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood (2006) 3.00
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood (2003) 2.60
Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood (2008) 2.15
Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment. Haematologica (2006) 1.84
Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience. J Clin Oncol (2013) 1.80
Somatic diversification in the absence of antigen-driven responses is the hallmark of the IgM+ IgD+ CD27+ B cell repertoire in infants. J Exp Med (2008) 1.75
Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. J Clin Oncol (2009) 1.69
Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission. J Clin Oncol (2009) 1.64
Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol (2012) 1.60
Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res (2008) 1.56
Plasmodium falciparum--infected erythrocyte adhesion induces caspase activation and apoptosis in human endothelial cells. J Infect Dis (2003) 1.44
The Paramecium germline genome provides a niche for intragenic parasitic DNA: evolutionary dynamics of internal eliminated sequences. PLoS Genet (2012) 1.38
Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J Immunol (2008) 1.28
Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood (2003) 1.24
Arginases in parasitic diseases. Trends Parasitol (2003) 1.21
A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood (2002) 1.21
Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy. Haematologica (2013) 1.18
Destructive arthritis in a patient with chikungunya virus infection with persistent specific IgM antibodies. BMC Infect Dis (2009) 1.18
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood (2007) 1.13
Quercetin induces apoptosis of Trypanosoma brucei gambiense and decreases the proinflammatory response of human macrophages. Antimicrob Agents Chemother (2004) 1.09
Simultaneous maintenance of human cord blood SCID-repopulating cells and expansion of committed progenitors at low O2 concentration (3%). Stem Cells (2004) 1.09
Monomeric and oligomeric flavanols are agonists of membrane androgen receptors. Exp Cell Res (2005) 1.08
Chronic rejection triggers the development of an aggressive intragraft immune response through recapitulation of lymphoid organogenesis. J Immunol (2010) 1.05
Non-Mendelian inheritance and homology-dependent effects in ciliates. Adv Genet (2002) 1.05
Hypoxia-inducible factor-1alpha, a key factor in the keratinocyte response to UVB exposure. J Biol Chem (2007) 1.04
Therapeutic and preventive properties of quercetin in experimental arthritis correlate with decreased macrophage inflammatory mediators. Biochem Pharmacol (2006) 1.03
Platelet-associated CD154 in immune thrombocytopenic purpura. Blood (2004) 1.03
Resveratrol exerts its antiproliferative effect on HepG2 hepatocellular carcinoma cells, by inducing cell cycle arrest, and NOS activation. Biochim Biophys Acta (2006) 1.01
Hypoxia maintains and interleukin-3 reduces the pre-colony-forming cell potential of dividing CD34(+) murine bone marrow cells. Exp Hematol (2002) 1.01
Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death. Cancer Biol Ther (2011) 1.00
Very low O2 concentration (0.1%) favors G0 return of dividing CD34+ cells. Stem Cells (2005) 1.00
Developmentally programmed DNA splicing in Paramecium reveals short-distance crosstalk between DNA cleavage sites. Nucleic Acids Res (2008) 0.99
Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission: results of a European survey. J Clin Oncol (2002) 0.98
Rutoside decreases human macrophage-derived inflammatory mediators and improves clinical signs in adjuvant-induced arthritis. Arthritis Res Ther (2008) 0.96
IL-17 in the rheumatologist's line of sight. Biomed Res Int (2013) 0.95
Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience. J Clin Oncol (2005) 0.95
Sensitivity of cardiac background inward rectifying K+ outward current (IK1) to the alkaloids lepadiformines A, B, and C. J Nat Prod (2006) 0.95
Hematopoietic stem cell transplantation for de novo erythroleukemia: a study of the European Group for Blood and Marrow Transplantation (EBMT). Blood (2002) 0.95
Carbon-14 biolabelling of wine polyphenols in Vitis vinifera cell suspension cultures. J Biotechnol (2002) 0.94
ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib. Exp Hematol (2012) 0.93
Synthesis of new pyrrolo[1,2-a]quinoxaline derivatives as potential inhibitors of Akt kinase. J Enzyme Inhib Med Chem (2008) 0.93
Preparative isolation of polyphenolic compounds from Vitis vinifera by centrifugal partition chromatography. J Chromatogr A (2002) 0.92
Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results. Haematologica (2007) 0.92
Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS. J Clin Oncol (2010) 0.92
Flt3-ligand induces adhesion of haematopoietic progenitor cells via a very late antigen (VLA)-4- and VLA-5-dependent mechanism. Br J Haematol (2003) 0.92
Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures. Neuro Oncol (2012) 0.91
ATRA-induced upregulation of Beclin 1 prolongs the life span of differentiated acute promyelocytic leukemia cells. Autophagy (2011) 0.90
IgE mediates killing of intracellular Toxoplasma gondii by human macrophages through CD23-dependent, interleukin-10 sensitive pathway. PLoS One (2011) 0.90
Metabonomic assessment of physiological disruptions using 1H-13C HMBC-NMR spectroscopy combined with pattern recognition procedures performed on filtered variables. Anal Chem (2002) 0.90
Proteomic analysis of an imatinib-resistant K562 cell line highlights opposing roles of heat shock cognate 70 and heat shock 70 proteins in resistance. Proteomics (2008) 0.89
Vasorelaxant effects of grape polyphenols in rat isolated aorta. Possible involvement of a purinergic pathway. Fundam Clin Pharmacol (2003) 0.89
CD95 triggers Orai1-mediated localized Ca2+ entry, regulates recruitment of protein kinase C (PKC) β2, and prevents death-inducing signaling complex formation. Proc Natl Acad Sci U S A (2011) 0.88
Triptolide cooperates with chemotherapy to induce apoptosis in acute myeloid leukemia cells. Exp Hematol (2008) 0.88
Proteasome inhibition specifically sensitizes leukemic cells to anthracyclin-induced apoptosis through the accumulation of Bim and Bax pro-apoptotic proteins. Cancer Biol Ther (2007) 0.86
Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study. Am J Hematol (2012) 0.86
Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571. Br J Haematol (2002) 0.86
Derivative (7)t(7;8)(q34;q21). a new additional cytogenetic abnormality in acute promyelocytic leukemia. Cancer Genet Cytogenet (2003) 0.86
(2-Arylhydrazonomethyl)-substituted xanthones as antimycotics: synthesis and fungistatic activity against Candida species. Eur J Med Chem (2002) 0.86
Synthesis, analytical behaviour and biological evaluation of new 4-substituted pyrrolo[1,2-a]quinoxalines as antileishmanial agents. Bioorg Med Chem (2006) 0.86
Quercetin exhibits a specific fluorescence in cellular milieu: a valuable tool for the study of its intracellular distribution. J Agric Food Chem (2007) 0.85
Molecular blocking of CD23 supports its role in the pathogenesis of arthritis. PLoS One (2009) 0.85
Overexpression of high molecular weight FGF-2 forms inhibits glioma growth by acting on cell-cycle progression and protein translation. Exp Cell Res (2008) 0.85
Xanthones from the seeds of Allanblackia monticola and their apoptotic and antiproliferative activities. Planta Med (2008) 0.85
Telomerase functions beyond telomere maintenance in primary cutaneous T-cell lymphoma. Blood (2014) 0.84
Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines. Cancer (2005) 0.84
Occupation and lymphoid malignancies: results from a French case-control study. J Occup Environ Med (2007) 0.83
CD23 mediates antimycobacterial activity of human macrophages. Infect Immun (2009) 0.82
Evaluation of antitumor effects of two vine stalk oligomers of resveratrol on a panel of lymphoid and myeloid cell lines: comparison with resveratrol. Life Sci (2007) 0.81
Quercetin accumulates in nuclear structures and triggers specific gene expression in epithelial cells. J Nutr Biochem (2011) 0.81